| Mr Ammad Asad Syed, MD | |
|
327 Medical Park Dr, Bridgeport, WV 26330-9006 | |
| (681) 342-1000 | |
| Not Available |
| Full Name | Mr Ammad Asad Syed |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 8 Years |
| Location | 327 Medical Park Dr, Bridgeport, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841647526 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 30301 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| United Hospital Center | Bridgeport, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| United Physicians Care Inc | 6103814017 | 103 |
News Archive
Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data of its novel gene-silencing oligonucleotide technology including observations that demonstrate GSOs exert gene-silencing activity through a similar cellular pathway as siRNA.
Parents may plan for transportation and childcare ahead of holiday gatherings but are they prepared for a potential, day-after "parenting hangover?"
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.
Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure.
› Verified 5 days ago
| Entity Name | United Physicians Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891863874 PECOS PAC ID: 6103814017 Enrollment ID: O20040706001382 |
News Archive
Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data of its novel gene-silencing oligonucleotide technology including observations that demonstrate GSOs exert gene-silencing activity through a similar cellular pathway as siRNA.
Parents may plan for transportation and childcare ahead of holiday gatherings but are they prepared for a potential, day-after "parenting hangover?"
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.
Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Ammad Asad Syed, MD 1978 Industrial Blvd., Internal Medicine Residency Program, Chabert Medical Ce, Houma, LA 70363 Ph: (985) 873-2710 | Mr Ammad Asad Syed, MD 327 Medical Park Dr, Bridgeport, WV 26330-9006 Ph: (681) 342-1000 |
News Archive
Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data of its novel gene-silencing oligonucleotide technology including observations that demonstrate GSOs exert gene-silencing activity through a similar cellular pathway as siRNA.
Parents may plan for transportation and childcare ahead of holiday gatherings but are they prepared for a potential, day-after "parenting hangover?"
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.
Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure.
› Verified 5 days ago
Dr. Vigneshwaran Ramanathan, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 327 Medical Park Dr, Bridgeport, WV 26330 Phone: 681-342-1000 | |
Dr. Keith Iverson Harrop Ii, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 327 Medical Park Dr, Bridgeport, WV 26330 Phone: 681-342-1000 | |
Dr. Sean Rogers, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 327 Medical Park Dr, Bridgeport, WV 26330 Phone: 681-342-1000 |